|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mizrahi JD, Surana R, Valle JW and Shroff
RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rothenberg ML, Moore MJ, Cripps MC,
Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG,
Brown TD, Casper ES, et al: A phase II trial of gemcitabine in
patients with 5-FU-refractory pancreas cancer. Ann Oncol.
7:347–353. 1996.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mao Y, Xi L, Li Q, Wang S, Cai Z, Zhang X
and Yu C: Combination of PI3K/Akt pathway inhibition and Plk1
depletion can enhance chemosensitivity to gemcitabine in pancreatic
carcinoma. Transl Oncol. 11:852–863. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Di Marco M, Di Cicilia R, Macchini M,
Nobili E, Vecchiarelli S, Brandi G and Biasco G: Metastatic
pancreatic cancer: Is gemcitabine still the best standard
treatment? (review). Oncol Rep. 23:1183–1192. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Loos M, Kleeff J, Friess H and Büchler MW:
Surgical treatment of pancreatic cancer. Ann N Y Acad Sci.
1138:169–180. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bidard FC, Pierga JY, Soria JC and Thiery
JP: Translating metastasis-related biomarkers to the
clinic-progress and pitfalls. Nat Rev Clin Oncol. 10:169–179.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Thalgott M, Heck MM, Eiber M, Souvatzoglou
M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M,
Gschwend JE, et al: Circulating tumor cells versus objective
response assessment predicting survival in metastatic
castration-resistant prostate cancer patients treated with
docetaxel chemotherapy. J Cancer Res Clin Oncol. 141:1457–1464.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Giuliano M, Giordano A, Jackson S, De
Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, et
al: Circulating tumor cells as early predictors of metastatic
spread in breast cancer patients with limited metastatic
dissemination. Breast Cancer Res. 16(440)2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Iinuma H, Watanabe T, Mimori K, Adachi M,
Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M
and Mori M: Clinical significance of circulating tumor cells,
including cancer stem-like cells, in peripheral blood for
recurrence and prognosis in patients with Dukes' stage B and C
colorectal cancer. J Clin Oncol. 29:1547–1555. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584.
2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Barriere G, Riouallon A, Renaudie J,
Tartary M and Rigaud M: Mesenchymal characterization: Alternative
to simple CTC detection in two clinical trials. Anticancer Res.
32:3363–3369. 2012.PubMed/NCBI
|
|
14
|
Arnoletti JP, Zhu X, Almodovar AJ,
Veldhuis PP, Sause R, Griffith E, Corpus G, Chang JC, Fanaian N and
Litherland SA: Portal venous blood circulation supports
immunosuppressive environment and pancreatic cancer circulating
tumor cell activation. Pancreas. 46:116–123. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tien YW, Kuo HC, Ho BI, Chang MC, Chang
YT, Cheng MF, Chen HL, Liang TY, Wang CF, Huang CY, et al: A high
circulating tumor cell count in portal vein predicts liver
metastasis from periampullary or pancreatic cancer: A high portal
venous CTC count predicts liver metastases. Medicine (Baltimore).
95(e3407)2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Effenberger KE, Schroeder C, Hanssen A,
Wolter S, Eulenburg C, Tachezy M, Gebauer F, Izbicki JR, Pantel K
and Bockhorn M: Improved risk stratification by circulating tumor
cell counts in pancreatic cancer. Clin Cancer Res. 24:2844–2850.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Han L, Chen W and Zhao Q: Prognostic value
of circulating tumor cells in patients with pancreatic cancer: A
meta-analysis. Tumour Biol. 35:2473–2480. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kurihara T, Itoi T, Sofuni A, Itokawa F,
Tsuchiya T, Tsuji S, Ishii K, Ikeuchi N, Tsuchida A, Kasuya K, et
al: Detection of circulating tumor cells in patients with
pancreatic cancer: A preliminary result. J Hepatobiliary Pancreat
Surg. 15:189–195. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Dotan E, Alpaugh RK, Ruth K, Negin BP,
Denlinger CS, Hall MJ, Astsaturov I, McAleer C, Fittipaldi P,
Thrash-Bingham C, et al: Prognostic significance of MUC-1 in
circulating tumor cells in patients with metastatic pancreatic
adenocarcinoma. Pancreas. 45:1131–1135. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ko AH, Scott J, Tempero MA and Park JW:
Detection and significance of circulating tumor cells (CTC) in
patients with metastatic pancreatic cancer (PC) receiving systemic
therapy. J Clin Oncol. 25 (Suppl 18)(S4596)2007.
|
|
21
|
Allen PJ, Kuk D, Castillo CF, Basturk O,
Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide
V, He J, et al: Multi-institutional validation study of the
American joint commission on cancer (8th edition) changes for T and
N staging in patients with pancreatic adenocarcinoma. Ann Surg.
265:185–191. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Liang X, Li X, Chang J, Duan Y and Li Z:
Properties and evaluation of quaternized chitosan/lipid cation
polymeric liposomes for cancer-targeted gene delivery. Langmuir.
29:8683–8693. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liang X, Tian H, Luo H, Wang H and Chang
J: Novel quaternized chitosan and polymeric micelles with
cross-linked ionic cores for prolonged release of minocycline. J
Biomater Sci Polym Ed. 20:115–131. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen J, Chen L, Du S, Wu J, Quan M, Yin H,
Wu Y, Ye X, Liang X and Jiang H: High sensitive detection of
circulating tumor cell by multimarker lipid magnetic nanoparticles
and clinical verifications. J Nanobiotechnology.
17(116)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Timme-Bronsert S, Bronsert P, Werner M,
Kulemann B and Höppner J: Circulating tumor cells in pancreatic
cancer: Results of morphological and molecular analyses and
comparisons with the primary tumor. Pathologe. 39 (Suppl
2):S311–S314. 2018.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
27
|
Zhao XH, Wang ZR, Chen CL, Di L, Bi ZF, Li
ZH and Liu YM: Molecular detection of epithelial-mesenchymal
transition markers in circulating tumor cells from pancreatic
cancer patients: Potential role in clinical practice. World J
Gastroenterol. 25:138–150. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Martini V, Timme-Bronsert S,
Fichtner-Feigl S, Hoeppner J and Kulemann B: Circulating tumor
cells in pancreatic cancer: Current perspectives. Cancers (Basel).
11(1659)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ducreux M, Cuhna AS, Caramella C,
Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van
Laethem JL, Conroy T, et al: Cancer of the pancreas: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 26 (Suppl 5):v56–v68. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tadros S, Shukla SK, King RJ, Gunda V,
Vernucci E, Abrego J, Chaika NV, Yu F, Lazenby AJ, Berim L, et al:
De novo lipid synthesis facilitates gemcitabine resistance through
endoplasmic reticulum stress in pancreatic cancer. Cancer Res.
77:5503–5517. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shukla SK, Purohit V, Mehla K, Gunda V,
Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, et
al: MUC1 and HIF-1alpha signaling crosstalk induces anabolic
glucose metabolism to impart gemcitabine resistance to pancreatic
cancer. Cancer Cell. 32:71–87.e7. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mehla K and Singh PK: Metabolic subtyping
for novel personalized therapies against pancreatic cancer. Clin
Cancer Res. 26:6–8. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Earl J, Garcia-Nieto S, Martinez-Avila JC,
Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E,
Lobo E, Malats N, et al: Circulating tumor cells (CTC) and KRAS
mutant circulating free DNA (cfDNA) detection in peripheral blood
as biomarkers in patients diagnosed with exocrine pancreatic
cancer. BMC Cancer. 15(797)2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Liu H, Sun B, Wang S, Liu C, Lu Y, Li D
and Liu X: Circulating tumor cells as a biomarker in pancreatic
ductal adenocarcinoma. Cell Physiol Biochem. 42:373–382.
2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
El Amrani M, Corfiotti F, Corvaisier M,
Vasseur R, Fulbert M, Skrzypczyk C, Deshorgues AC, Gnemmi V,
Tulasne D, Lahdaoui F, et al: Gemcitabine-induced
epithelial-mesenchymal transition-like changes sustain
chemoresistance of pancreatic cancer cells of mesenchymal-like
phenotype. Mol Carcinog. 58:1985–1997. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Xie N, Hu Z, Tian C, Xiao H, Liu L, Yang
X, Li J, Wu H, Lu J, Gao J, et al: In vivo detection of CTC and CTC
plakoglobin status helps predict prognosis in patients with
metastatic breast cancer. Pathol Oncol Res. 26:2435–2442.
2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kimura K, Amano R, Nakata B, Yamazoe S,
Hirata K, Murata A, Miura K, Nishio K, Hirakawa T, Ohira M and
Hirakawa K: Clinical and pathological features of five-year
survivors after pancreatectomy for pancreatic adenocarcinoma. World
J Surg Oncol. 12(360)2014.PubMed/NCBI View Article : Google Scholar
|
